Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Entia Biosciences Inc Receives Notices Of Allowance For Ergothioneine And Genetic Transporter Patents From United States, Canada And Israel

Tuesday, 2 Apr 2013 12:10pm EDT 

Entia Biosciences Inc announced that it has now received three Patent Notices of Allowance covering the use of Ergothioneine and its genetic transporter in the treatment of a wide variety of diseases, including those affecting the immune and central nervous systems. Notices from the United States Patent and Trademark Office and the Israel Patent Office were received in March and from the Canadian Intellectual Property Office in December. Ergothioneine is a powerful amino acid and master antioxidant that is acquired exclusively from the diet and carried by a unique and specific transporter (human gene symbol SLC22A4) to cells throughout the body that are fighting damage and death from oxidative stress and toxic free radical reactions. Research conducted by Entia since 2011 has confirmed significant transporter activity in diabetes, arthritis, and several other serious non-communicable chronic conditions, suggesting an important physiologic role for Ergothioneine and its transporter in diseases affecting millions of people world-wide. 

Company Quote

0.04 +16.67%
16 Dec 2014